IL33 and inflammatory bowel disease: Although it therefore appears likely that IL-33/ST2 signaling might represent a feasible target in PSC and IBD, there is no published data that reports the effect of an IL-33/ST2 signaling blockade on fibrosis in either PSC or IBD to our knowledge whatsoever.